Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Aimmune Therapeutics Inc (AIMT)

NASDAQ
Currency in USD
Disclaimer
34.49
0.00(0.00%)
Closed

AIMT Comments

why it stopped the transaction anybody knows please ?
Nestlé bought all the available stock in the market.
short this stock, whats up?
the rocket it s close, hold on boooooooys
What is happening?
this will explode hardly.
they were waiting for me to buy in....now it launches
did this stock froze .whats going on
Yeah I’m confused too
Yes this is great news....but NEVER hold for some made up price like $75. There is always chop in the market and its always, always, always a good idea to take profits. Good Luck
Ahahaha, thats what I am talking about I am rich, dont sell guys before $75
sell or hold here?
Hold it , are you kidding me ?
new to the game never had a company sell on me
sell or hold here?
How much are you up?
Hold wait till $75
Not that this is KODAK but, that deal was only 750 million. This is 2 Billion. I'd say this still has some room to move.
11.99 and below is easy returns
absolutely agree,  I am buying heavy.
love to hear it
they just made a deal this could be big
Beware of recommendations given by analysts! More than 2/3 are worthless.
Is this a good entry price?  15.81.?
guys get ready for fast jump!
Why?
very interesting that people are selling because of poor earnings. I mean, what do you expect, their groundbreaking drug got approved in the midst of a pandemic. oh well, gotta buy more to use this chance then.
Buy this stock, In a year will go over 50$ !!!
I hope I didnt wrote this :(
why Mr. Nasdaq Digger is still 17.64 usd ? even Nestle from Switzerland they bought some millions of shares ? what happens here ? can you advise us please ? to purchase or not ?
APPROVED by FDA ....Amazing stock should go to $42 this week of Feb 3rd 2020... who knows from there..
So I guess FDA forgot about Palforzia?
approved
God damnit I watch for so long and I miss it
AMT ...hitting l$40 within 30 to 60 days...!!!!!
why is it going down?
Quick primer to help new visitors: FDA approval of $AIMT Palforzia peanut allergy treatment should come any time between now and late January.. . Consensus rev est for Palforzia is $55M, but Piper Jaffray recently did survey; analyst said he saw crazy disconnect, that “survey indicates 'massive upside'” to rev estimates that could top $1B in 2020 (18x greater than consensus) and $1.9B in 2021!. . thefly.com/landingPageNews..... . EU approval by summer, then Asia. There is no meaningful competition.. . AIMT also has solid pipeline, with treatments for egg, tree nut, and milk allergies.. . At $30.80, AIMT’s market cap is only $1.9B. Imagine buying a company for only 1x expected revenue, valuing zero for that pipeline! The value is insane.. . And the short interest is 23% of the float! The squeeze could be epic, even biblical!. . Nestle owns 19% of the AIMT, buying millions of shares in Nov 2018 for $30.27, and buyout is likely.. . Many analysts have targets at $60-$80, which sounds reasonable.
AIMMUNE'S immune therapy to help those suffering with fear of death with peanut allergies is on the fast tract. This is a one of a kind drug therapy that is already proven to have great response! Now is the time to buy before complete approval which is coming up soon.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.